Titre : Visiteurs des patients

Visiteurs des patients : Questions médicales fréquentes

Termes MeSH sélectionnés :

Checkpoint Kinase 2
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Visiteurs des patients : Questions médicales les plus fréquentes", "headline": "Visiteurs des patients : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Visiteurs des patients : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-31", "dateModified": "2025-03-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Visiteurs des patients" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Personnes", "url": "https://questionsmedicales.fr/mesh/D009272", "about": { "@type": "MedicalCondition", "name": "Personnes", "code": { "@type": "MedicalCode", "code": "D009272", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "M01" } } }, "about": { "@type": "MedicalCondition", "name": "Visiteurs des patients", "alternateName": "Visitors to Patients", "code": { "@type": "MedicalCode", "code": "D014789", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Samantha J Chiew", "url": "https://questionsmedicales.fr/author/Samantha%20J%20Chiew", "affiliation": { "@type": "Organization", "name": "Animal Welfare Science Centre, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, North Melbourne, VIC, Australia." } }, { "@type": "Person", "name": "Paul H Hemsworth", "url": "https://questionsmedicales.fr/author/Paul%20H%20Hemsworth", "affiliation": { "@type": "Organization", "name": "Animal Welfare Science Centre, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, North Melbourne, VIC, Australia." } }, { "@type": "Person", "name": "Sally L Sherwen", "url": "https://questionsmedicales.fr/author/Sally%20L%20Sherwen", "affiliation": { "@type": "Organization", "name": "Department of Wildlife Conservation and Science, Zoos Victoria, Parkville, VIC, Australia." } }, { "@type": "Person", "name": "Grahame J Coleman", "url": "https://questionsmedicales.fr/author/Grahame%20J%20Coleman", "affiliation": { "@type": "Organization", "name": "Animal Welfare Science Centre, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, North Melbourne, VIC, Australia." } }, { "@type": "Person", "name": "Vicky Melfi", "url": "https://questionsmedicales.fr/author/Vicky%20Melfi", "affiliation": { "@type": "Organization", "name": "Hartpury University and Hartpury College, Gloucester, United Kingdom." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.", "datePublished": "2024-01-10", "url": "https://questionsmedicales.fr/article/38200372", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00011-023-01833-w" } }, { "@type": "ScholarlyArticle", "name": "Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease.", "datePublished": "2023-11-30", "url": "https://questionsmedicales.fr/article/38161833", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7759/cureus.49710" } }, { "@type": "ScholarlyArticle", "name": "Expression of the checkpoint kinase BUB1 is a predictor of response to cancer therapies.", "datePublished": "2024-02-23", "url": "https://questionsmedicales.fr/article/38396175", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-55080-y" } }, { "@type": "ScholarlyArticle", "name": "Spindle Position Checkpoint Kinase Kin4 Regulates Organelle Transport in", "datePublished": "2023-07-10", "url": "https://questionsmedicales.fr/article/37509134", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/biom13071098" } }, { "@type": "ScholarlyArticle", "name": "Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: Design, synthesis, cytotoxicity evaluation, and mechanistic insights.", "datePublished": "2024-05-19", "url": "https://questionsmedicales.fr/article/38823311", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.bioorg.2024.107471" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Personnes", "item": "https://questionsmedicales.fr/mesh/D009272" }, { "@type": "ListItem", "position": 3, "name": "Visiteurs des patients", "item": "https://questionsmedicales.fr/mesh/D014789" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Visiteurs des patients - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Visiteurs des patients", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Visiteurs des patients", "description": "Comment évaluer l'impact des visites sur le patient ?\nQuels signes indiquent qu'un patient a besoin de visites ?", "url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Checkpoint+Kinase+2&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Visiteurs des patients", "description": "Quels symptômes peuvent s'aggraver sans visites ?\nLes visites peuvent-elles réduire la douleur perçue ?", "url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Checkpoint+Kinase+2&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Visiteurs des patients", "description": "Comment prévenir l'isolement des patients ?\nQuelles mesures prendre pour des visites sûres ?", "url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Checkpoint+Kinase+2&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Visiteurs des patients", "description": "Les visites font-elles partie du traitement ?\nComment les hôpitaux gèrent-ils les visites ?", "url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Checkpoint+Kinase+2&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Visiteurs des patients", "description": "Quelles complications peuvent survenir sans visites ?\nLes visites peuvent-elles causer du stress au patient ?", "url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Checkpoint+Kinase+2&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Visiteurs des patients", "description": "Quels facteurs augmentent le besoin de visites ?\nLes patients en soins intensifs ont-ils plus besoin de visites ?", "url": "https://questionsmedicales.fr/mesh/D014789?mesh_terms=Checkpoint+Kinase+2&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'impact des visites sur le patient ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'impact peut être évalué par des questionnaires sur le bien-être et l'état émotionnel." } }, { "@type": "Question", "name": "Quels signes indiquent qu'un patient a besoin de visites ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Un patient peut montrer des signes de solitude, d'anxiété ou de dépression." } }, { "@type": "Question", "name": "Quels symptômes peuvent s'aggraver sans visites ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'isolement social peut aggraver l'anxiété et la dépression chez le patient." } }, { "@type": "Question", "name": "Les visites peuvent-elles réduire la douleur perçue ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le soutien émotionnel des visiteurs peut diminuer la perception de la douleur." } }, { "@type": "Question", "name": "Comment prévenir l'isolement des patients ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Encourager les visites régulières et utiliser des technologies de communication." } }, { "@type": "Question", "name": "Quelles mesures prendre pour des visites sûres ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Respecter les protocoles d'hygiène et les restrictions de visite en place." } }, { "@type": "Question", "name": "Les visites font-elles partie du traitement ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les visites peuvent être considérées comme un complément au traitement médical." } }, { "@type": "Question", "name": "Comment les hôpitaux gèrent-ils les visites ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les hôpitaux établissent des horaires et des règles pour assurer la sécurité des patients." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir sans visites ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "L'absence de visites peut entraîner une détérioration de la santé mentale et physique." } }, { "@type": "Question", "name": "Les visites peuvent-elles causer du stress au patient ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des visites non planifiées ou trop fréquentes peuvent causer du stress." } }, { "@type": "Question", "name": "Quels facteurs augmentent le besoin de visites ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé, les maladies chroniques et l'isolement social augmentent ce besoin." } }, { "@type": "Question", "name": "Les patients en soins intensifs ont-ils plus besoin de visites ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients en soins intensifs peuvent bénéficier davantage du soutien des visiteurs." } } ] } ] }

Sources (10000 au total)

Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.

Janus kinase 2 (JAK2) mutation plays an important role in T cell immunity. However, the effect of JAK2 mutation on immunotherapy is largely uncharacterized.... In this study, we analyzed the effect of JAK2 mutation on the efficacy and outcomes of immune checkpoint inhibitor (ICI) therapy in the discovery cohort (n = 662) and the verification cohort (n = 1423... In the discovery cohort (n = 662), JAK2 mutant-type patients had a better objective response rate (58.8% vs. 26.7%, P = 0.010), durable clinical benefit (64.7% vs. 38.9%, P = 0.043), progression-free ... Our study demonstrates that JAK2 mutation is a novel marker that can be used to effectively predict prognosis and response to ICI therapy....

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.

This study aimed to evaluate the effectiveness and safety of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) plus tyrosine kinase inhibitors (TKIs) (TACE... Data of consecutive advanced HCC patients receiving TACE+IT or IT between January 2019 and December 2021 were included and were retrospectively analyzed. Propensity score matching (PSM) was performed ... Sixty-four patients were enrolled in the study, among which 24 and 40 received TACE+IT and IT, respectively. The PSM cohort included 24 patients receiving TACE+IT (TACE+IT group) and 24 patients recei... TACE combined with ICIs plus TKIs significantly improved OS, ORR, and DCR and showed a relatively longer PFS trend over ICIs combined with TKIs for advanced HCC....

Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors.

The survival rate of patients with cancer has been increasing because of the sustained anticancer effect of new drugs, such as immune checkpoints inhibitors (ICI). Unlike the existing cytotoxic chemot... Using the claims data from the Health Insurance Review and Assessment service in Korea, we retrospectively investigated patients with cancer who received chemotherapy between January 1, 2014 and Febru... Of all patients with cancer (n = 665,445) who received all kinds of chemotherapy, those who have received ICI accounted for 1.91 %. Compare with cytotoxic chemotherapy and angiogenesis inhibitors (AIs... This study showed a synergistic effect in patients who received multiple administrations of a drug that might be associated with thyroid dysfunction. Therefore, special attention should be paid to the...